|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitchell AL, Gandhi A, Scott-Coombes D and
Perros P: Management of thyroid cancer: United kingdom national
multidisciplinary guidelines. J Laryngol Otol. 130:S150–S160. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi RL, Qu N, Yang SW, Ma B, Lu ZW, Wen D,
Sun GH, Wang Y and Ji QH: Tumor size interpretation for predicting
cervical lymph node metastasis using a differentiated thyroid
cancer risk model. Onco Targets Ther. 9:5015–5022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang TS, Dubner S, Sznyter LA and Heller
KS: Incidence of metastatic well-differentiated thyroid cancer in
cervical lymph nodes. Arch Otolaryngol Head Neck Surg. 130:110–113.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hay ID, Grant CS, van Heerden JA, Goellner
JR, Ebersold JR and Bergstralh EJ: Papillary thyroid
microcarcinoma: A study of 535 cases observed in a 50-year period.
Surgery. 112:1139–1147. 1992.PubMed/NCBI
|
|
6
|
Lang BH, Ng SH, Lau LL, Cowling BJ, Wong
KP and Wan KY: A systematic review and meta-analysis of
prophylactic central neck dissection on short-term locoregional
recurrence in papillary thyroid carcinoma after total
thyroidectomy. Thyroid. 23:1087–1098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hundahl SA, Cady B, Cunningham MP,
Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK
and Hölzer S: Initial results from a prospective cohort study of
5583 cases of thyroid carcinoma treated in the united states during
1996. U.S. and German thyroid cancer study group. An American
college of surgeons commission on cancer patient care evaluation
study. Cancer. 89:202–217. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ain KB: Radioiodine-remnant ablation in
low-risk differentiated thyroid cancer. Pros Endocrine. 50:61–66.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schlumberger M, Catargi B, Borget I,
Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D,
Schvartz C, et al: Strategies of radioiodine ablation in patients
with low-risk thyroid cancer. N Engl J Med. 366:1663–1673. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee YM, Cho JY, Sung TY, Kim TY, Chung KW,
Hong SJ and Yoon JH: Clinicopathological risk factors and
biochemical predictors of safe discharge after total thyroidectomy
and central compartment node dissection for thyroid cancer: A
prospective study. Int J Endocrinol. 2015:2145252015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia Q, Meng Z, Tan J, Zhang G, He Y, Sun
H, Yu C, Li D, Zheng W, Wang R, et al: Retrospective imaging study
on the diagnosis of pathological false positive iodine-131 scans in
patients with thyroid cancer. Exp Ther Med. 10:1995–2001. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hackshaw A, Harmer C, Mallick U, Haq M and
Franklyn JA: 131I activity for remnant ablation in patients with
differentiated thyroid cancer: A systematic review. J Clin
Endocrinol Metab. 92:28–38. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, . Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised
American Thyroid Association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid.
19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harding LK: Radiation protection
legislation. Eur J Nucl Med. 25:187–191. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alexander C, Bader JB, Schaefer A, Finke C
and Kirsch CM: Intermediate and long-term side effects of high-dose
radioiodine therapy for thyroid carcinoma. J Nucl Med.
39:1551–1554. 1998.PubMed/NCBI
|
|
17
|
Chang H, Yoo RN, Kim SM, Kim BW, Lee YS,
Lee SC, Chang HS and Park CS: The clinical significance of the
right para-oesophageal lymph nodes in papillary thyroid cancer.
Yonsei Med J. 56:1632–1637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gulcelik MA, Ozdemir Y, Kadri Colakoglu M,
Camlibel M and Alagol H: Prognostic factors determining survival in
patients with node positive differentiated thyroid cancer: A
retrospective cross-sectional study. Clin Otolaryngol. 37:460–467.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
American Thyroid Association Surgery
Working Group; American Association of Endocrine Surgeons, American
Academy of Otolaryngology-Head and Neck Surgery, American Head and
Neck Society, . Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT,
Mandel SJ, et al: Consensus statement on the terminology and
classification of central neck dissection for thyroid cancer.
Thyroid. 19:1153–1158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bal CS, Kumar A and Pant GS: Radioiodine
dose for remnant ablation in differentiated thyroid carcinoma: A
randomized clinical trial in 509 patients. J Clin Endocrinol Metab.
89:1666–1673. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
M E, l-Refaei S, W Yassin S, Salman K, Al
Munshy T, Al-Ezzi M, M Al-Sayed Y and Abd Elkareem Husseni M:
Comparison between low and high radioactive iodine (131I)
reablation dose in patients with papillary thyroid cancer. Nucl Med
Commun. 36:114–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lim YC, Liu L, Chang JW and Koo BS:
Lateral lymph node recurrence after total thyroidectomy and central
neck dissection in patients with papillary thyroid cancer without
clinical evidence of lateral neck metastasis. Oral Oncol.
62:109–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wagieh SM, El-Refaei SM, Salem SS,
Al-Shiekh EA, Al-Ghamdy HA and Al-Juhani NR: Impact of
histopathology of non-neoplastic thyroid tissue on ablation outcome
in patients with papillary thyroid cancer. Nucl Med Commun.
32:597–604. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pacini F, Schlumberger M, Harmer C, Berg
GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, et al:
Post-surgical use of radioiodine (131I) in patients with papillary
and follicular thyroid cancer and the issue of remnant ablation: A
consensus report. Eur J Endocrinol. 153:651–659. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsang RW, Brierley JD, Simpson WJ,
Panzarella T, Gospodarowicz MK and Sutcliffe SB: The effects of
surgery, radioiodine, and external radiation therapy on the
clinical outcome of patients with differentiated thyroid carcinoma.
Cancer. 82:375–388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McCowen KD, Adler RA, Ghaed N, Verdon T
and Hofeldt FD: Low dose radioiodide thyroid ablation in
postsurgical patients with thyroid cancer. Am J Med. 61:52–58.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Prpic M, Dabelic N, Stanicic J, Jukic T,
Milosevic M and Kusic Z: Adjuvant thyroid remnant ablation in
patients with differentiated thyroid carcinoma confined to the
thyroid: A comparison of ablation success with different activities
of radioiodine (I-131). Ann Nucl Med. 26:744–751. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Higashi T, Nishii R, Yamada S, Nakamoto Y,
Ishizu K, Kawase S, Togashi K, Itasaka S, Hiraoka M, Misaki T and
Konishi J: Delayed initial radioactive iodine therapy resulted in
poor survival in patients with metastatic differentiated thyroid
carcinoma: A retrospective statistical analysis of 198 cases. J
Nucl Med. 52:683–689. 2012. View Article : Google Scholar
|
|
29
|
Tsirona S, Vlassopoulou V, Tzanela M,
Rondogianni P, Ioannidis G, Vassilopoulos C, Botoula E, Trivizas P,
Datseris I and Tsagarakis S: Impact of early vs late postoperative
radioiodine remnant ablation on final outcome in patients with
low-risk well-differentiated thyroid cancer. Clin Endocrinol (Oxf).
80:459–463. 2014. View Article : Google Scholar : PubMed/NCBI
|
